<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2011-3515-998-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="SV">Reglering av immunglobulinsyntes hos patienter med prim&#xE4;r immunbrist</narrative>
   <narrative xml:lang="EN">Regulation of immunoglobulin synthesis in primary immunodeficiency in man</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Prim&#xE4;r immunbrist hos m&#xE4;nniska - diagnostik och behandling Variabel immunbrist (CVID) och selektiv IgA brist (IgAD) &#xE4;r de vanligast f&#xF6;rekommande formerna av prim&#xE4;r immunbrist i Sverige och totalt finns cirka 15 000 patienter i landet. P&#xE5; grund av bristen p&#xE5; antikroppar drabbas patienterna av frekventa infektioner och behandlas d&#xE4;rf&#xF6;r regelm&#xE4;ssigt med gammaglobulin och antibiotika. Den genetiska orsaken till sjukdomarna &#xE4;r fortfarande ok&#xE4;nd (mindre &#xE4;n 10 % av patienterna har f&#xE5;tt en molekyl&#xE4;rt baserad diagnos) och avsikten med v&#xE5;rt projekt &#xE4;r att identifiera ytterligare gener som orsakar dessa defekter. Vidare syftar projektet till att f&#xF6;rs&#xF6;ka f&#xF6;rst&#xE5; den starka koppling som finns mellan IgA brist och autoimmuna sjukdomar som diabetes och glutenintolerans. CVID och IgA brist har tidigare betraktats som obotbara sjukdomar men vi har nyligen funnit ett tiotal patienter som gradvis normaliserat sina immunglobulinniv&#xE5;er. Detta talar f&#xF6;r att defekten kan vara av regulatorisk art vilket kan vara av mycket stor betydelse f&#xF6;r att finna en alternativ framtida behandling f&#xF6;r v&#xE5;ra patienter. Vi vill d&#xE4;rf&#xF6;r f&#xF6;rs&#xF6;ka utveckla nya behandlingsmetoder baserade p&#xE5; stimulering av de vita blodkropparna (lymfocyter) med olika signalsubstanser (cytokiner) via modifierade laktobaciller (lokal produktion i tarmen med hj&#xE4;lp av vanliga youghurt-bakterier) eller genom re-programmering av patientens egna celler fr&#xE5;n blodet (inducerbara pluripotenta stamceller). Modifierade laktobaciller som producerar antikroppar mot selekterade smitt&#xE4;mnen (bakterier och virus) kommer ocks&#xE5; att genereras och kan utg&#xF6;ra ett framtida behandlingsalternativ vid vissa infektionssjukdomar orsakade av rotavirus, norovirus och HIV.</narrative>
   <narrative xml:lang="EN">The suggested project is focused on two main themes - immunogenetics and immunotherapy - using state of the art (and beyond state of the art) technologies. Selective IgA deficiency (IgAD) and common variable immunodeficiency (CVID) are the two most common forms of primary immunodeficiency diseases (PID) in Sweden. Although both diseases have a strong genetic component, the genes involved have only been identified in a minority of patients (less than 10 %). The main aim of the proposed project is to identify novel genes associated with these diseases. Thus far, all primary immunodeficiency diseases have been found to be monogenic. IgAD and CVID are the first primary immunodeficiency which may be polygenic, involving both MHC and non-MHC genes. Finding these genes would represent the *next generation* in identifying the etiology of PID. A second objective of our studies is to develop novel forms of replacement or even curative therapy for our PID patients and other groups of infectious prone patients.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Karolinska Institutet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2012-01-01" type="1"></activity-date>
  <activity-date iso-date="2012-01-01" type="3"></activity-date>
  <activity-date iso-date="2014-12-31" type="2"></activity-date>
  <activity-date iso-date="2014-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2013-01-01"></period-start>
   <period-end iso-date="2013-12-28"></period-end>
   <value currency="USD" value-date="2013-01-01">130504.2068414911</value>
  </budget>
  <budget>
   <period-start iso-date="2014-01-01"></period-start>
   <period-end iso-date="2014-12-28"></period-end>
   <value currency="USD" value-date="2014-01-01">123908.5117858861</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2011-10-27"></transaction-date>
   <value currency="USD" value-date="2011-10-27">392960.6114775319</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2014-01-28"></transaction-date>
   <value currency="USD" value-date="2014-01-28">123908.5117858861</value>
  </transaction>
  <document-link format="APPLICATION/PDF" url="http://upload.openaid.se/document/vetenskapsradet/generalla-villkor-2012.pdf">
   <title>
    <narrative xml:lang="SV">Generella bidragsvillkor 2012</narrative>
   </title>
   <category code="A04"></category>
  </document-link>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
